


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	WELSH, Michael J.
				Art Unit	1649
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	P04404US01

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
WJ WJ	2	WO 98/35034	08/13/1998	WALDMANN		
	3	WO 00/08149	02/17/2000	WALDMANN		

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).. ² See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³

Applicant's unique citation designation number (optional).³ See Kind or USPTO Patent documents at www.uspto.gov or MPEC 901.04.
Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

ENTERED 08/18/2003 *WJ*

Form PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	WELSH, Michael J.
				Group Art Unit	1699
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	P04404US01

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>WJ</i>	4	ASKWITH et al., "FMRFamide-related peptides potentiate acid-evoked currents from sensory neurons and DEG/ENaC channels", Society for Neuroscience Abstracts, 2000, No. 18.4.	
	5	ASKWITH et al., Neuron, 26(1)133-41, April 2000	
	6	KRIEGLER, M., "Gene Transfer and Expression: A Laboratory Manual", pp. 3-176, Stockton Press, NY, NY 1990	
	7	LOPES et al., "Actions of general anaesthetics and arachidonic acid pathway inhibitors on K ⁺ currents activated by volatile anaesthetics and FMRFamide in molluscan neurons", British Journal of Pharmacology, 1998, 125.2:309-318	
	8	O'GARA et al., "Regulation of pharyngeal motility by FMRFamide and related peptides in the medical leech, Hirudo medicinalis", Invertebrate Neuroscience, 1999, 4:41-53.	
	9	PERRY et al., J. Neuroscience, 21(15) 5559-5567, 2001	
	10	PRICE et al., "Cloning and Expression of a Novel Human Brain Na ⁺ Channel", The J. of Biological Chem. 271(14):7879-7882 1996	
	11	SAKAI et al., "Cloning and functional expression of a novel degenerin-line Na ⁺ channel gene in mammals", Journal of Physiology, 1999, 519.2:323-333	
	12	WALDMANN et al., "The Mammalian Degenerin MDEG, an Amiloride-sensitive Cation Channel Activated by Mutations Causing Neurodegeneration in <i>Caenorhabditis elegans</i> ", The J. of Biological Chem. 271(18):10433-10436 1996.	

Examiner Signature	<i>Michael J. Welsh</i>	Date Considered	12/3/05
--------------------	-------------------------	-----------------	---------

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.